No clinically significant pharmacokinetic interactions between dolutegravir and daclatasvir in healthy adult subjects.

ABSTRACT:

Background

Daclatasvir (DCV) is an NS5A replication complex inhibitor recently approved for chronic hepatitis C virus treatment.

Methods

To assess drug interactions between the HIV integrase strand transfer inhibitor dolutegravir (DTG) and DCV, subjects were randomized into 1 of 2 sequences in an open-label, 3-period, crossover study. Subjects received either DTG 50 mg once daily or DCV 60 mg once daily for 5 days in periods 1 and 2 and DTG 50 mg plus DCV 60 mg once daily for 5 days in period 3, with no washout between periods 2 and 3. Between periods 1 and 2, there was a washout period of at least 7 days.

Results

The geometric least-squares mean ratios (90 % confidence intervals) of DCV area under the concentration-time curve over a dosing interval (AUC0-τ), maximum

SUBMITTER: Ross LL 

PROVIDER: S-EPMC4957413 | biostudies-literature | 2016 Jul

REPOSITORIES: biostudies-literature